Mizuho Cuts DENTSPLY SIRONA (NASDAQ:XRAY) Price Target to $14.00

DENTSPLY SIRONA (NASDAQ:XRAY) had its price target decreased by Mizuho from $16.00 to $14.00 in a research note issued to investors on Wednesday morning,Benzinga reports. Mizuho currently has a neutral rating on the medical instruments supplier’s stock.

A number of other analysts also recently commented on XRAY. UBS Group decreased their price target on DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Zacks Research raised DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Barrington Research increased their price target on DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a research report on Monday, March 2nd. Wells Fargo & Company increased their price target on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Finally, Citigroup initiated coverage on DENTSPLY SIRONA in a research report on Wednesday, April 15th. They set a “sell” rating and a $10.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, DENTSPLY SIRONA currently has an average rating of “Hold” and an average target price of $13.82.

DENTSPLY SIRONA Stock Up 0.4%

XRAY stock opened at $11.00 on Wednesday. DENTSPLY SIRONA has a twelve month low of $9.85 and a twelve month high of $17.18. The company has a quick ratio of 1.03, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. The stock’s 50 day moving average is $12.07 and its 200-day moving average is $12.00. The firm has a market capitalization of $2.20 billion, a PE ratio of -3.49, a P/E/G ratio of 1.30 and a beta of 0.93.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The company had revenue of $880.00 million during the quarter, compared to the consensus estimate of $841.80 million. During the same quarter in the prior year, the business earned $0.43 EPS. The firm’s revenue for the quarter was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts expect that DENTSPLY SIRONA will post 1.42 EPS for the current fiscal year.

Insider Buying and Selling at DENTSPLY SIRONA

In other news, Director Gregory T. Lucier bought 15,000 shares of the stock in a transaction on Monday, March 9th. The shares were purchased at an average cost of $12.45 per share, for a total transaction of $186,750.00. Following the completion of the purchase, the director directly owned 65,000 shares in the company, valued at $809,250. This represents a 30.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James D. Forbes bought 5,000 shares of the stock in a transaction on Monday, March 9th. The stock was purchased at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the purchase, the director owned 10,000 shares of the company’s stock, valued at approximately $124,800. This trade represents a 100.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders acquired 70,000 shares of company stock worth $956,437. Corporate insiders own 0.50% of the company’s stock.

Institutional Trading of DENTSPLY SIRONA

Several hedge funds have recently made changes to their positions in the company. PNC Financial Services Group Inc. raised its stake in shares of DENTSPLY SIRONA by 211.1% in the first quarter. PNC Financial Services Group Inc. now owns 14,070 shares of the medical instruments supplier’s stock valued at $163,000 after buying an additional 9,547 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of DENTSPLY SIRONA by 31.4% in the first quarter. Dimensional Fund Advisors LP now owns 3,559,388 shares of the medical instruments supplier’s stock valued at $41,284,000 after buying an additional 850,261 shares during the period. Heartland Advisors Inc. raised its stake in shares of DENTSPLY SIRONA by 490.6% in the first quarter. Heartland Advisors Inc. now owns 953,250 shares of the medical instruments supplier’s stock valued at $11,058,000 after buying an additional 791,850 shares during the period. Jennison Associates LLC bought a new stake in shares of DENTSPLY SIRONA in the first quarter valued at $12,439,000. Finally, John G Ullman & Associates Inc. bought a new stake in shares of DENTSPLY SIRONA in the first quarter valued at $269,000. 95.70% of the stock is currently owned by institutional investors.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.